Financial News

Biotech CEO: Bayh-Dole 'fix' won't lower drug prices

A proposal to amend Bayh-Dole won’t, in fact, have the intended impact of reducing drug prices, writes John Glasspool, CEO of Anthos Therapeutics Inc. in Cambridge.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Feedback